Frequency of benign tumors after partial nephrectomy and the association between malignant tumor findings and preoperative clinical parameters.
Benign
Carcinoma, renal cell
Incidence
Kidney tumors
Pathology
Journal
BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571
Informations de publication
Date de publication:
22 Aug 2024
22 Aug 2024
Historique:
received:
29
04
2023
accepted:
15
07
2024
medline:
23
8
2024
pubmed:
23
8
2024
entrez:
22
8
2024
Statut:
epublish
Résumé
Partial nephrectomy (PN) has become the dominant treatment modality for cT1 renal tumor lesions. Tumors suspected of malignant potential are indicated for surgery, but some are histologically classified as benign lesions after surgery. This study aims to analyze the number of benign findings after PN according to definitive histology and to evaluate whether there is an association between malignant tumor findings and individual factors. The retrospective study included 555 patients who underwent open or robotic-assisted PN for a tumor in our clinic from January 2013 to December 2020. The cohort was divided into groups according to definitive tumor histology (malignant tumors vs. benign lesions). The association of factors (age, sex, tumor size, R.E.N.A.L.) with the malignant potential of the tumor was further evaluated. In total, 462 tumors were malignant (83%) and 93 benign (17%). Of the malignant tumors, 66% were clear-cell RCC (renal cell carcinoma), 12% papillary RCC, and 6% chromophobe RCC. The most common benign tumor was oncocytoma in 10% of patients, angiomyolipoma in 2%, and papillary adenoma in 1%. In univariate analysis, there was a higher risk of malignant tumor in males (OR 2.13, 95% CI 1.36-3.36, p = 0.001), a higher risk of malignancy in tumors larger than 20 mm (OR 2.32, 95% CI 1.43-3.74, p < 0.001), and a higher risk of malignancy in tumors evaluated by R.E.N.A.L. as tumors of intermediate or high complexity (OR 2.8, 95% CI 1.76-4.47, p < 0.001). In contrast, there was no association between older age and the risk of malignant renal tumor (p = 0.878). In this group, 17% of tumors had benign histology. Male sex, tumor size greater than 20 mm, and intermediate or high R.E.N.A.L. complexity were statistically significant predictors of malignant tumor findings.
Sections du résumé
BACKGROUND
BACKGROUND
Partial nephrectomy (PN) has become the dominant treatment modality for cT1 renal tumor lesions. Tumors suspected of malignant potential are indicated for surgery, but some are histologically classified as benign lesions after surgery. This study aims to analyze the number of benign findings after PN according to definitive histology and to evaluate whether there is an association between malignant tumor findings and individual factors.
METHODS
METHODS
The retrospective study included 555 patients who underwent open or robotic-assisted PN for a tumor in our clinic from January 2013 to December 2020. The cohort was divided into groups according to definitive tumor histology (malignant tumors vs. benign lesions). The association of factors (age, sex, tumor size, R.E.N.A.L.) with the malignant potential of the tumor was further evaluated.
RESULTS
RESULTS
In total, 462 tumors were malignant (83%) and 93 benign (17%). Of the malignant tumors, 66% were clear-cell RCC (renal cell carcinoma), 12% papillary RCC, and 6% chromophobe RCC. The most common benign tumor was oncocytoma in 10% of patients, angiomyolipoma in 2%, and papillary adenoma in 1%. In univariate analysis, there was a higher risk of malignant tumor in males (OR 2.13, 95% CI 1.36-3.36, p = 0.001), a higher risk of malignancy in tumors larger than 20 mm (OR 2.32, 95% CI 1.43-3.74, p < 0.001), and a higher risk of malignancy in tumors evaluated by R.E.N.A.L. as tumors of intermediate or high complexity (OR 2.8, 95% CI 1.76-4.47, p < 0.001). In contrast, there was no association between older age and the risk of malignant renal tumor (p = 0.878).
CONCLUSIONS
CONCLUSIONS
In this group, 17% of tumors had benign histology. Male sex, tumor size greater than 20 mm, and intermediate or high R.E.N.A.L. complexity were statistically significant predictors of malignant tumor findings.
Identifiants
pubmed: 39174947
doi: 10.1186/s12894-024-01543-3
pii: 10.1186/s12894-024-01543-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
175Informations de copyright
© 2024. The Author(s).
Références
Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, Gore JL, Sun M, Wood C, Russo P. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75(1):74–84.
doi: 10.1016/j.eururo.2018.08.036
pubmed: 30243799
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
Ljunberg B, Albiges L, Bedke J, Bex A, Capitanio U, Giles R, Hora M, Klatte T, Lam T, Marconi L, Powles T, Volpe A. Guidelines on renal cell carcinoma. https://uroweb.org/guidelines/renal-cell-carcinoma . (Accessed: 13th January 2023).
Furrer MA, Spycher SCJ, Büttiker SM, Gross T, Bosshard P, Thalmann GN, Schneider MP, Roth B. Comparison of the diagnostic performance of contrast-enhanced Ultrasound with that of contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging in the evaluation of renal masses: a systematic review and Meta-analysis. Eur Urol Oncol. 2020;3(4):464–73.
doi: 10.1016/j.euo.2019.08.013
pubmed: 31570270
Basile G, Fallara G, Verri P, Uleri A, Chiti A, Gianolli L, Pepe G, Tedde A, Algaba F, Territo A, Sanguedolce F, Larcher A, Gallioli A, Palou J, Montorsi F, Capitanio U, Breda A. The role of 99mTc-Sestamibi single-photon Emission Computed Tomography/Computed Tomography in the diagnostic pathway for renal masses: a systematic review and Meta-analysis. Eur Urol. 2024;85(1):63–71.
doi: 10.1016/j.eururo.2023.07.013
pubmed: 37673752
Bauman TM, Potretzke AM, Wright AJ, Knight BA, Vetter JM, Figenshau RS. Partial nephrectomy for presumed renal-cell carcinoma: incidence, predictors, and Pe-rioperative outcomes of Benign lesions. J Endourol. 2017;31(4):412–7.
doi: 10.1089/end.2016.0667
pubmed: 28068796
Richard PO, Jewett MA, Bhatt JR et al. Renal tumor biopsy for small renal masses: a single-center 13-year experience. Eur Urol Apr 18 2015.
Halverson SJ, Kunju LP, Bhalla R, et al. Accuracy of determining small renal mass management with risk stratified biopsies: confirmation by final pathology. J Urol Feb. 2013;189(2):441–6.
doi: 10.1016/j.juro.2012.09.032
Çalışkan S, Gümrükçü G, Özsoy E, Topaktas R, Öztürk Mİ. Renal angiomyolipoma. Rev Assoc Med Bras (1992). 2019;65(7):977–81.
doi: 10.1590/1806-9282.65.7.977
pubmed: 31389508
Fujii Y, Komai Y, Saito K, et al. Incidence of benign pathologic lesions at partial nephrectomy for presumed RCC renal masses: Japanese dual-center experience with 176 consecutive patients. Urol Sep. 2008;72(3):598–602.
doi: 10.1016/j.urology.2008.04.054
Jeon HG, Lee SR, Kim KH, et al. Benign lesions after partial nephrectomy for presumed renal cell carcinoma in masses 4 cm or less: prevalence and predictors in Korean patients. Urol Sep. 2010;76(3):574–9.
doi: 10.1016/j.urology.2009.11.082
Kutikov A, Fossett LK, Ramchandani P, et al. Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging. Urol Oct. 2006;68(4):737–40.
doi: 10.1016/j.urology.2006.04.011
Lindkvist Pedersen C, Winck-Flyvholm L, Dahl C, Azawi NH. High rate of benign histology in radiologically suspect renal lesions. Dan Med J Oct. 2014;61(10):A4932.
McKiernan J, Yossepowitch O, Kattan MW, et al. Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. Urol 12//. 2002;60(6):1003–9.
doi: 10.1016/S0090-4295(02)01967-2
Marszalek M, Ponholzer A, Brossner C, Wachter J, Maier U, Madersbacher S. Elective open nephron-sparing surgery for renal masses: single-center experience with 129 consecutive patients. Urol Jul. 2004;64(1):38–42.
doi: 10.1016/j.urology.2004.02.007
Snyder ME, Bach A, Kattan MW, Raj GV, Reuter VE, Russo P. Incidence of benign lesions for clinically localized renal masses smaller than 7 cm in radiological diameter: influence of sex. J Urol. 2006;176(6 Pt 1):2391-5; discussion 2395-6. https://doi.org/10.1016/j.juro.2006.08.013 . PMID: 17085108.
Nguyen KA, Brito J, Hsiang W, Nolte A, Syed JS, Suarez-Sarmiento A, Leapman MS, Shuch B. National trends and economic impact of surgical treatment for benign kidney tumors. Urol Oncol. 2019;37(3):183.e9-183.e15.
Kay FU, Pedrosa I, Imaging of Solid Renal Masses. Urol Clin North Am. 2018;45(3):311–30. https://doi.org/10.1016/j.ucl.2018.03.013 . Epub 2018 Jun 15. PMID: 30031457; PMCID: PMC6057157.
doi: 10.1016/j.ucl.2018.03.013
pubmed: 30031457
pmcid: 6057157
Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, Marechal JM, Klotz L, Skinner E, Keane T, Claessens I, Sylvester R, European Organization for Research and Treatment of Cancer (EORTC); National Cancer Institute of Canada Clinical Trials Group (NCIC CTG); Southwest Oncology Group (SWOG). Eastern Cooperative Oncology Group (ECOG). A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2007;51(6):1606–15. https://doi.org/10.1016/j.eururo.2006.11.013 .
doi: 10.1016/j.eururo.2006.11.013
pubmed: 17140723
Mottrie A, De Naeyer G, Schatteman P, Carpentier P, Sangalli M, Ficarra V. Impact of the learning curve on perioperative outcomes in patients who underwent robotic partial nephrectomy for parenchymal renal tumours. Eur Urol. 2010;58(1):127–32. https://doi.org/10.1016/j.eururo.2010.03.045 .
doi: 10.1016/j.eururo.2010.03.045
pubmed: 20399002
Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009;182(3):844–53.
doi: 10.1016/j.juro.2009.05.035
pubmed: 19616235
Corcoran AT, Russo P, Lowrance WT, Asnis-Alibozek A, Libertino JA, Pryma DA, Divgi CR, Uzzo RG. A review of contemporary data on surgically resected renal masses–benign or malignant? Urology. 2013;81(4):707–13.
doi: 10.1016/j.urology.2013.01.009
pubmed: 23453080
Park SY, Jeon SS, Lee SY, Jeong BC, Seo SI, Lee HM, Choi HY. Incidence and predictive factors of Benign Renal lesions in Korean patients with preoperative imaging diagnoses of renal cell carcinoma. J Korean Med Sci. 2011;26(3):360364.
doi: 10.3346/jkms.2011.26.3.360
Mauermann J, de Martino M, Waldert M, Haitel A, Klingler HC, Remzi M, Klatte T. Gender differences in benign renal masses. World J Urol. 2013;31(5):1051–7.
doi: 10.1007/s00345-013-1032-4
pubmed: 23417319
Nandanan N, Veccia A, Antonelli A, Derweesh I, Mottrie A, Minervini A, Aron M, Simone G, Capitanio U, Simeone C, Eun D, Perdonà S, Porter J, Sundaram C, Zhang C, Uzzo R, Challacombe B, Hampton LJ, Kaouk J, Porpiglia F. Autori-no R. outcomes and predictors of benign histology in patients undergoing robotic partial or radical nephrectomy for renal masses: a multicenter stu-dy. Cent Eur J Urol. 2020;73(1):33–8.
Srougi V, Kato RB, Salvatore FA, Ayres PP, Dall’Oglio MF, Srougi M. Incidence of benign lesions according to tumor size in solid renal masses. Int Braz J Urol. 2009 Jul-Aug;35(4):427 – 31. https://doi.org/10.1590/s1677-55382009000400005 . PMID: 19719857.
Schachter LR, Cookson MS, Chang SS, Smith JA Jr, Dietrich MS, Jayaram G, Herrell SD. Second prize: frequency of benign renal cortical tumors and histologic subtypes based on size in a contemporary series: what to tell our patients. J Endourol. 2007;21(8):819 – 23. https://doi.org/10.1089/end.2006.9937 . PMID: 17867935.
Wang R, Wolf JS Jr, Wood DP Jr, Higgins EJ, Hafez KS. Accuracy of percutaneous core biopsy in management of small renal masses. Urology. 2009;73(3):586–90.
Volpe A, Mattar K, Finelli A, Kachura JR, Evans AJ, Geddie WR, Jewett MA. Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience. J Urol. 2008;180(6):2333–7.
doi: 10.1016/j.juro.2008.08.014
pubmed: 18930274
Kang SK, Huang WC, Pandharipande PV, Chandarana H. Solid renal masses: what the numbers tell us. AJR Am J Roentgenol. 2014;202(6):1196–206.
doi: 10.2214/AJR.14.12502
pubmed: 24848816
pmcid: 4174582
DeLong W, Grignon DJ, Eberwein P, Shum DT, Wyatt JK. Sarcomatoid renal cell carcinoma. An immunohistochemical study of 18 cases. Arch Pathol Lab Med. 1993;117(6):636–40.
pubmed: 7684893
Schuster AH, Reimann N. Biopsien Von Nierenläsionen: wann und wie? [Biopsies of kidney lesions: when and how?]. Radiologe. German. 2018;58(10):906–13. https://doi.org/10.1007/s00117-018-0459-4 .
doi: 10.1007/s00117-018-0459-4
pubmed: 30291407
Schlomer B, Figenshau RS, Yan Y, Bhayani SB. How does the radiographic size of a renal mass compare with the pathologic size? Urology. 2006;68(2):292–5.
doi: 10.1016/j.urology.2006.03.004
pubmed: 16904439